文献速递前列腺癌

度他雄胺对磁共振成像定义的前列腺癌的影响:MAPPED-A随机、安慰剂对照、双盲临床试验

The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
PubMed 文献 · J Urol · 2016-11-19

这项随机双盲安慰剂对照试验纳入42例活检证实为低至中危前列腺癌(Gleason评分不超过3+4且PSA不超过15 ng/ml)且T2加权磁共振成像可见病灶≥0.2 ml的男性,随机接受每日度他雄胺0.5 mg或安慰剂治疗6个月。度他雄胺组病灶体积平均缩小36%,安慰剂组平均增大12%,组间缩小百分比差异为48%(95%CI 27.4-68.3,P<0.0001)。

要点

  • 度他雄胺组6个月病灶体积平均缩小36%,安慰剂组平均增大12%。
  • 组间缩小百分比差异为48%(95%CI 27.4-68.3,P<0.0001)。
  • 最常见不良事件为勃起功能减退,度他雄胺组25%,安慰剂组16%。

核心结论

  • 与安慰剂相比,度他雄胺与T2加权磁共振成像上前列腺癌体积显著缩小相关。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入42例活检证实的低至中危前列腺癌男性(Gleason评分不超过3+4且PSA不超过15 ng/ml),T2加权磁共振成像可见病灶≥0.2 ml。

主要发现

  • 度他雄胺组基线及6个月平均病灶体积分别为0.55 ml和0.38 ml,平均缩小36%。
  • 安慰剂组基线及6个月平均病灶体积分别为0.65 ml和0.76 ml,平均缩小-12%。
  • 两组缩小百分比差异为48%(95%CI 27.4-68.3,P<0.0001)。
  • 最常见不良事件为勃起功能减退,度他雄胺组为25%,安慰剂组为16%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dutasteride, which is licensed for symptomatic benign prostatic hyperplasia, has been associated with a lower progression rate of low risk prostate cancer. We evaluated the effect of dutasteride on prostate cancer volume as assessed by T2-weighted magnetic resonance imaging. MATERIALS AND METHODS: In this randomized, double-blind, placebo controlled trial, men with biopsy proven, low-intermediate risk prostate cancer (up to Gleason 3 + 4 and PSA up to 15 ng/ml) who had visible lesion of 0.2 ml or greater on T2-weighted magnetic resonance imaging sequences were randomized to daily dutasteride 0.5 mg or placebo for 6 months. Lesion volume was assessed at baseline, and 3 and 6 months with image guided biopsy to the lesion at study exit. The primary end point was the percent reduction in lesion volume over 6 months. This trial was registered with the European Clinical Trials register (EudraCT 2009-102405-18). RESULTS: A total of 42 men were recruited between June 2010 and January 2012. In the dutasteride group, the average volumes at baseline and 6 months were 0.55 and 0.38 ml, respectively and the average reduction was 36%. In the placebo group, the average volumes at baseline and 6 months were 0.65 and 0.76 ml, respectively, and the average reduction was -12%. The difference in percent reductions between the groups was 48% (95% CI 27.4-68.3, p <0.0001). The most common adverse event was deterioration in erectile function, which was 25% in men randomized to dutasteride and 16% in men randomized to placebo. CONCLUSIONS: Dutasteride was associated with a significant reduction in prostate cancer volume on T2-weighted magnetic resonance imaging compared to placebo.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Moore CM, Robertson NL, Jichi F, et al. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial. J Urol. 2016. PMID: 27871928. doi:10.1016/j.juro.2016.11.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。